Mesoblast Stock

Mesoblast EBIT

Delisted·Jun 19, 2026

The EBIT of Mesoblast (MSB.AX) as of Jul 26, 2026 is -82.30 M USD. In the previous year, EBIT was -66.89 M USD — a change of 23.04% (lower).

EBIT

-82.30 MUSD

YoY

23.04%

Last updated:

In 2026, Mesoblast's EBIT was -82.30 M USD, a 23.04% increase from the -66.89 M USD EBIT recorded in the previous year.

The Mesoblast EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2024
-66.89 base
Jan 1, 2025
-82.30 base
Jan 1, 2026 (e)
-21.18 base
Jan 1, 2027 (e)
42.67 base
Jan 1, 2028 (e)
207.75 base
Jan 1, 2029 (e)
546.15 base
Jan 1, 2030 (e)
614.88 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (M USD)
2031 est -
2030 est 614.88
2029 est 546.15
2028 est 207.75
2027 est 42.67
2026 est -21.18
2025 -82.30
2024 -66.89
2023 -62.72
2022 -73.76
2021 -90.39
2020 -73.49
2019 -86.47
2018 -64.31
2017 -90.17
2016 -18.47
2015 -91.79
2014 -67.85
2013 -61.60
2012 -50.24
2011 -7.79
2010 -9.14
2009 -6.93
2008 -7.10
2007 -5.50
2006 -4.70
Access this data via the Eulerpool API

Mesoblast Revenue

Mesoblast Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
5.90 M USD
-66.89 M USD
-87.96 M USD
Jan 1, 2025
17.20 M USD
-82.30 M USD
-102.14 M USD
Jan 1, 2026 (e)
128.05 M USD
-21.18 M USD
-171.81 M USD
Jan 1, 2027 (e)
177.61 M USD
42.67 M USD
0.00 USD
Jan 1, 2028 (e)
353.69 M USD
207.75 M USD
442.76 M USD
Jan 1, 2029 (e)
968.95 M USD
546.15 M USD
730.46 M USD
Jan 1, 2030 (e)
942.00 M USD
614.88 M USD
0.00 USD
Jan 1, 2031 (e)
1.37 B USD
0.00 USD
0.00 USD

Mesoblast Margins

Mesoblast stock margins

The Mesoblast margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mesoblast. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mesoblast.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
-166.30 %
-1,133.28 %
-1,490.27 %
Jan 1, 2025
70.17 %
-478.51 %
-593.92 %
Jan 1, 2026 (e)
70.17 %
-16.54 %
-134.17 %
Jan 1, 2027 (e)
70.17 %
24.03 %
0.00 %
Jan 1, 2028 (e)
70.17 %
58.74 %
125.18 %
Jan 1, 2029 (e)
70.17 %
56.37 %
75.39 %
Jan 1, 2030 (e)
70.17 %
65.27 %
0.00 %
Jan 1, 2031 (e)
70.17 %
0.00 %
0.00 %

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Mesoblast's EBIT

Mesoblast's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Mesoblast's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Mesoblast's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Mesoblast’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Mesoblast stock

EBIT of Mesoblast is -82.30 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Mesoblast

All Key Metrics — Mesoblast